American Society of Hematology (ASH) 2012 Converage

ASH 2012

ASH: Asparaginase Erwinia Chrysanthemi ‘Well Tolerated’ Among Patients with ALL and L-ASP Allergy

Asparaginase Erwinia chrysanthemi (marketed as Erwinaze) is well tolerated among children and young adults diagnosed with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to the Escherichia coli-derived L-asparaginase (L-ASP), according to compassionate use protocol data presented during the 54th American Society of Hematology Annual Meeting and Exposition. L-ASP is part of standard chemotherapy regimens for ALL.

ASH: PACE: Superior Molecular Response to Ponatinib in Chronic Myeloid Leukemia (CML)

Ponatinib treatment is associated with significant molecular response rates among patients intolerant to dasatinib and nilotinib or who have dasatimib- and nilotinib-resistant chronic myeloid leukemia (CML), according to an analysis of data from the open-label multinational phase 2 PACE clinical trial. The analysis was presented during the 54th American Society of Hematology Annual Meeting and Exposition.

ASH: Quizartinib “Promising” for Relapsed, Refractory AML

Quizartinib is a promising treatment for refractory and relapsed acute myeloid leukemia (AML) after second-line chemotherapy or hematopoietic stem cell transplantation (HSCT), according to a cohort analysis of data from an open-label phase 2 safety and efficacy study presented during the 54th American Society of Hematology Annual Meeting and Exposition.

Next post in ASH 2012